Amgen’s Phase II MariTide Data Lack Clarity Market Hoped For

Efficacy, Safety Data Pooled, Limited

 
• By Mandy Jackson
  
Analysts and investors need more data to measure MariTide's competitiveness (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Therapy Areas